153EGP
- Active ingredient
- carbidopa+levodopa
- Strength
- 25/250 mg
- Form
- tablet
- Manufacturer
- future pharmaceutical industries (fpi)
- Route
- oral.solid
Uses
Used for Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism from certain toxic exposures.
Do not use if
Contraindicated with nonselective MAO inhibitors and in patients with hypersensitivity to formulation components.
Side effects
Nausea, dizziness, dyskinesia, orthostatic hypotension, hallucinations, and insomnia may occur.
Warnings
Dose adjustment should be individualized. Monitor for psychiatric symptoms, dyskinesias, and sudden sleep episodes.
How it works
Levodopa is converted to dopamine in the brain, while carbidopa inhibits peripheral levodopa metabolism and enhances availability.
Storage
Store at room temperature and protect from moisture.
